This week’s lockdown of Shijiazhuang, a city of 11 million, is a reminder that sporadic flare-ups of COVID-19 are still imposing an economic cost on China. Domestic passenger travel in particular remains depressed. Vaccines hold the key to a full return to normality and so it’s encouraging that the phase 3 trial results announced in recent days suggest that China’s two main vaccine candidates are highly effective. We expect the rollout to be rapid, with much of the population inoculated by year-end.
Become a client to read more
This is premium content that requires an active Capital Economics subscription to view.
Already have an account?
You may already have access to this premium content as part of a paid subscription.
Sign in to read the content in full or get details of how you can access it
Register for free
Sign up for a free account to gain:
- Unlock additional content
- Register for Capital Economics events
- Receive email updates and economist-curated newsletters
- Request a free trial of our services